The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells
暂无分享,去创建一个
A. Balduini | P. Guglielmelli | G. Barosi | A. Vannucchi | P. Catarsi | V. Rosti | V. Poletto | L. Villani | R. Zappatore | M. Avanzini | L. Cobianchi | A. Rambaldi | M. Massa | A. Iurlo | C. D. Di Buduo | M. Boni | P. Bernasconi | M. Mantelli | S. Croce | E. Lenta | R. Campanelli | E. Bonetti | I. Dambruoso | S. Salmoiraghi | V. Abbonante | Basilio Jemos
[1] A. Balduini,et al. Altered fibronectin expression and deposition by myeloproliferative neoplasm‐derived mesenchymal stromal cells , 2016, British journal of haematology.
[2] M. Le Bousse-Kerdilès,et al. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis. , 2015, Cancer research.
[3] Daniel B. Aruch,et al. Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. , 2015, Blood.
[4] W. Aicher,et al. Matrix metalloproteinases in stem cell mobilization. , 2015, Matrix biology : journal of the International Society for Matrix Biology.
[5] D. Lai,et al. Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms , 2014, Nature.
[6] C. Weber,et al. Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells. , 2014, Stem cells and development.
[7] F. Locatelli,et al. Functional and genetic aberrations of in vitro-cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms , 2014, Leukemia.
[8] P. Guglielmelli,et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.
[9] I. Bruns,et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells , 2013, Leukemia.
[10] M. Paulli,et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. , 2013, Blood.
[11] J. Tripodi,et al. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. , 2012, The Journal of clinical investigation.
[12] M. Le Bousse-Kerdilès. Primary myelofibrosis and the "bad seeds in bad soil" concept , 2012, Fibrogenesis & tissue repair.
[13] M. L. Bousse-Kerdilès. Primary myelofibrosis and the "bad seeds in bad soil" concept , 2012 .
[14] A. Kalinkovich,et al. Regulatory cross talks of bone cells, hematopoietic stem cells and the nervous system maintain hematopoiesis. , 2012, Inflammation & allergy drug targets.
[15] Ulrich Keilholz,et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. , 2011, Blood.
[16] I. Ghobrial,et al. Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects , 2011, Clinical Cancer Research.
[17] A. Balduini,et al. Megakaryocyte-matrix interaction within bone marrow: new roles for fibronectin and factor XIII-A. , 2011, Blood.
[18] Ben D. MacArthur,et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche , 2010, Nature.
[19] R. Hoffman,et al. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. , 2010, Cancer research.
[20] Jérôme Larghero,et al. Bone marrow microenvironment in fanconi anemia: a prospective functional study in a cohort of fanconi anemia patients. , 2010, Stem cells and development.
[21] D. Kaplan,et al. Bone Marrow Osteoblastic Niche: A New Model to Study Physiological Regulation of Megakaryopoiesis , 2009, PloS one.
[22] A. Balduini,et al. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes , 2008, Journal of thrombosis and haemostasis : JTH.
[23] M. Le Bousse-Kerdilès,et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. , 2008, Blood.
[24] Daniel Lucas,et al. Haematopoietic stem cell release is regulated by circadian oscillations , 2008, Nature.
[25] A. Cometa,et al. Human Bone Marrow-Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-Term In Vitro Culture and Do Not Exhibit Telomere Maintenance Mechanisms. , 2007 .
[26] A. Cometa,et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms , 2010 .
[27] H. Hasselbalch,et al. The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disorders , 2007, British journal of haematology.
[28] T. Nagasawa,et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. , 2006, Immunity.
[29] Lindolfo da Silva Meirelles,et al. Mesenchymal stem cells reside in virtually all post-natal organs and tissues , 2006, Journal of Cell Science.
[30] P. Frenette,et al. Signals from the Sympathetic Nervous System Regulate Hematopoietic Stem Cell Egress from Bone Marrow , 2006, Cell.
[31] D. Scadden,et al. Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.
[32] G. Barosi,et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. , 2001, Blood.
[33] C. Overall,et al. Matrix Metalloproteinase Activity Inactivates the CXC Chemokine Stromal Cell-derived Factor-1* , 2001, The Journal of Biological Chemistry.
[34] Linzhao Cheng,et al. Human mesenchymal stem cells support megakaryocyte and pro‐platelet formation from CD34+ hematopoietic progenitor cells , 2000, Journal of cellular physiology.
[35] 杉山 立樹. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches , 2007 .
[36] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.